8-K: Amprius Technologies Faces NYSE Listing Compliance Issue Due to Low Share Price

Amprius Technologies has received a notice from the NYSE for not meeting the minimum average share price requirement, giving them six months to regain compliance.

Summary

• Amprius Technologies received a notice from the New York Stock Exchange (NYSE) on September 19, 2024, stating that they are not in compliance with the continued listing criteria.
• The non-compliance is due to the average closing price of Amprius' common stock being less than $1.00 over a consecutive 30 trading-day period.
• Amprius has six months from the date of the notice to regain compliance.
• To regain compliance, the company's stock must have a closing price of at least $1.00 per share on the last trading day of any calendar month during the six-month cure period.
• Additionally, the average closing share price must be at least $1.00 over the 30 trading-day period ending on the last trading day of that month or the last trading day of the cure period.
• The company intends to remain listed on the NYSE and is considering all available options to regain compliance.
• The notice does not currently affect the listing or trading of Amprius' common stock on the NYSE.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the non-compliance notice and the risk of delisting, although the company is taking steps to address the issue.

Positives

• The notice is a notice of deficiency, not delisting, and does not currently affect the listing or trading of the company's stock.
• Amprius has six months to regain compliance, providing time to address the issue.
• The company intends to remain listed on the NYSE and is actively exploring options to regain compliance.
• The notice is not anticipated to impact the ongoing business operations of the company or its reporting requirements with the SEC.

Negatives

• Amprius' stock price has fallen below the NYSE's minimum average closing price requirement of $1.00.
• The company is now at risk of being delisted if it cannot regain compliance within the six-month cure period.

Risks

• There is a risk that Amprius may not be able to regain compliance with the NYSE listing standards within the six-month cure period.
• Failure to regain compliance could result in the delisting of Amprius' common stock from the NYSE.
• The company's stock price may be negatively impacted by the non-compliance notice.
• The company's ability to raise capital may be affected by the non-compliance notice.

Future Outlook

Amprius intends to remain listed on the NYSE and is considering all available options to regain compliance with the NYSE's continued listing standards. The company has six months to regain compliance.

Management Comments

• The company intends to remain listed on the NYSE.
• Amprius is considering all available options to regain compliance with the NYSE's continued listing standards.

Industry Context

This announcement highlights the challenges faced by companies in the competitive battery technology sector, where market sentiment and stock performance can be volatile. It also underscores the importance of maintaining a strong stock price to meet exchange listing requirements.

Comparison to Industry Standards

• Many companies in the technology sector, especially those in the early stages of commercialization, face challenges in maintaining stock prices above minimum listing requirements.
• Other companies in the battery technology space have also experienced volatility in their stock prices due to market sentiment and the capital-intensive nature of the industry.
• The six-month cure period is a standard procedure for companies facing non-compliance issues with exchange listing rules.

Stakeholder Impact

• Shareholders may experience concern due to the non-compliance notice and the potential for delisting.
• Employees may be affected by the uncertainty surrounding the company's future listing status.
• Customers and suppliers may be impacted by the potential for disruption to the company's operations.

Next Steps

• Amprius must achieve a closing stock price of at least $1.00 on the last trading day of any month within the next six months.
• Amprius must also maintain an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month or the last trading day of the cure period.
• The company will explore all available options to regain compliance with the NYSE listing standards.

Key Dates

Keywords

NYSE, listing compliance, share price, delisting, Amprius Technologies, common stock, non-compliance, cure period